

FORM 51 – 102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Pascal Bioscience Inc.
280 7th Avenue East
Vancouver, BC V5T 0B4

2. Date of Material Change

July 16, 2018

3. News Release

News releases dated July 16, 2018 was disseminated through Marketwired and filed via SEDAR the same respective day.

4. Summary of the Material Change

Pascal Biosciences appoints Julie M. Eastland to its Board of Directors

5. Full Description of the Material Change

Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) announced on July 16, 2018 the appointment of Julie M. Eastland to the Board of Directors. Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in public and private biotechnology companies. Most recently she was Chief Business Officer and Chief Financial Officer of Cascadian Therapeutics, where she negotiated and managed the \$810M acquisition by Seattle Genetics in March 2018. “We are extremely pleased to have Julie Eastland join our Board of Directors,” stated Dr. Patrick Gray, CEO of Pascal. “Ms. Eastland possesses the financial and corporate development experience that Pascal will need going forward. She has previously raised over \$725M in both private and public offerings for Cascadian Therapeutics and other biotechnology companies. Ms. Eastland has strong relationships with investors, investment bankers and analysts covering the U.S. public biotech sector, and excellent experience in partnering, acquisitions, collaborations, and licensing. She will work closely with Pascal to align our scientific strategy with our financial goals.” Ms. Eastland commented, “I believe Pascal’s portfolio of immuno-oncology therapeutic candidates holds great promise, and I look forward to working with Dr. Gray and the rest of the Board to support the advancement of these programs to create value for patients and shareholders.”

Ms. Eastland served as Chief Business and Financial Officer of Cascadian Therapeutics, formerly Oncothyreon Inc., (Nasdaq:CASC and ONTY) from September 2010 to March 2018. From 2006 to 2010, Ms. Eastland was the Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately-held biotechnology company. Prior to VLST, Ms. Eastland held various financial and strategic management positions at publicly-traded biotechnology companies including Dendreon and Amgen. Ms. Eastland received an M.B.A. from Edinburgh University

Management School and a B.S. in finance from Colorado State University.

The Company has also announced the retirement of Dr. Reinhard Gabathuler from the Pascal Board of Directors. “We are indebted to Dr. Gabathuler for his work with Pascal, previously known as Biommune,” Dr. Gray commented, “On behalf of our board of directors, I would like to thank Gaba for his leadership and direction of the company, and I wish him the very best in his future endeavors.”

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Patrick W. Gray, President & CEO
Phone: 1-206-221-3443

9. Date of Report

July 24, 2018